期刊
ADVANCES IN CHRONIC KIDNEY DISEASE
卷 17, 期 5, 页码 420-427出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2010.06.002
关键词
Hemodialysis; Chronic kidney disease; Anticoagulation; Warfarin; Low-molecular-weight heparin; Heparin; Direct thrombin inhibitors
Anticoagulation therapy is commonly required in patients with chronic kidney disease for treatment or prevention of thromboembolic disorders. Anticoagulant management plans can involve use of a single agent, or in some cases, a combination of agents to meet both short- and long-term goals. Systemic anticoagulation in the setting of renal insufficiency poses unique challenges secondary to renal failure-associated hypercoagulable conditions and increased risks for bleeding. Evidence supporting dosing regimens and monitoring approaches in the setting of severe renal impairment or hemodialysis is limited because this population is typically excluded in clinical trials. This review explores concepts of systemic anticoagulation in the chronic kidney disease setting with warfarin, unfractionated heparin, low-molecular-weight heparin, fondaparinux, direct thrombin inhibitors, and anticoagulants in advanced stages of development. Potential strategies for anticoagulant reversal are also briefly described. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据